Kornimate/medical-research-clean huggingface dataset:
comparison of efficacy of hydrocortisone and methyl prednisolone in acute severe asthma

Conditions: Asthma Acute

Summary: comparison of efficacy of hydrocortisone and methylprednisolone in acute severe asthma in this study investigator will compare the efficacy of hydrocortisone and methyl prednisolone in acute severe asthma that will lead to final result and beneficial effects that will help in early resoloution of symptoms and help in preventing recurrence

investigator will compare the efficacy of hydrocortisone v/s methylprednisolone in management of patients presented with acute severe asthma in emergency. a local study was conducted in 2009, after that there is a big research gap exists at national level although international literature is available on the same but it can not be generalized to our population due to socio, geographic and economic differences so there is dire need to conduct this study this gives a strong rationale to implement in our settings

Eligibility criteria:
inclusion criteria: * either gender (18 to 50 years old) * patient presenting to emergency department with acute severe asthma exclusion criteria: * patients with critical illness or pregnant females. .patient treated other than hydrocortisone and methylprednisolone. .patients not willing to participate in study. * life threatening asthma * near fatal asthm
mirror grant - toward an understanding of body image adaptation following surgical treatment for head and neck cancer

Conditions: Head and Neck Cancer

Summary: the goal of this research study is to understand how patients adjust to appearance and body image changes after surgery for head and neck cancer.

if you agree to take part in this study, you will take part in a face-to-face interview with the study staff. it should take about 1 hour to complete. you will also be asked to complete a questionnaire about your demographic information such as age and ethnicity. the interview will be done in a private research area and will be audio-recorded. the researchers are interested in learning more about your experience of adjusting to the changes in your appearance after your surgery for head and neck cancer. you may be asked to look in a mirror and describe what you see. if you ask for another interview, or if the interviewer would like your information made more clear, you will be scheduled for a second interview. you will be provided with an early summary of your interview, and you will be able to provide feedback over the phone or in writing on the accuracy of the information and the conclusions. identifying information will be removed from all data collected using participant numbers kept separately from consent forms and shared only among approved research staff. names and other identifying information will be deleted from transcripts (write-ups of the interviews) after the first review for accuracy. interview transcripts will be kept in locked file cabinets at md anderson for 3 years and can be looked at only by the study chair and staff. recorded interviews will be destroyed 3 years after the study results are published. this is an investigational study. up to 20 patients and 15 healthcare providers will take part in this study. all will be enrolled at md anderson.

Eligibility criteria:
inclusion criteria: 1. at least 18 years of age 2. english speaking 3. for patients: within 6 weeks of undergoing surgical resection for a tumor in the head and neck region, or within 1-3 years from such surgery. 4. for providers: inpatient clinical staff (i.e. surgeons, nurses, nursing assistants, physical therapists) who care for surgically treated head and neck cancer patients during acute postoperative recovery, and/or outpatient clinical staff (i.e. nurses, physician assistants) who care for these patients throughout active treatment and into the period of survivorship. 5. for providers: having worked with surgically treated head and neck cancer patients for at least one year. exclusion criteria: 1) for patients: cognitive impairment documented in their medical record (e.g. delirium, dementia) impeding the ability to offer a narrative of his/her experience.

Keywords: head and neck cancer body image adaptation post surgical body image audio-recorded interview questionnaire survey
pulse oximetry in healthy subjects immerged in ocean.

Conditions: Drowning

Summary: drowning is the 3rd leading cause of accidental death in the world. one of the tools used by lifeguards to help er assess gravity, is pulse oximetry. its measure is variable even in optimal condition and its accuracy can be altered by factors specific to the patient and by environmental factors. the conditions gathered during a drowning rescue are thus propitious to a misleading evaluation. assessing its reliability and looking for influencing factors of the measure of pulse oximetry could help for pre-hospital care management.

the research focuses on the measurement of pulse oximetry among lifeguard on the atlantic coast of gironde, france, before and after their daily training, using a standardized measurement protocol. the follow-up will be done during the beach monitoring period during the summer of 2020. a total of 3 months of measurement collection is expected.

Eligibility criteria:
inclusion criteria: * lifeguard working on the girondine atlantic coast * up to 18 years old, * no smoker, * no chronic pathology. exclusion criteria: * chronic cardiac pathology, * chronic respiratory pathology, * acrosyndrome, * smoker.
initiative for molecular profiling in advanced cancer therapy (impact) trial, an umbrella protocol

Conditions: Advanced Cancers

Summary: primary objective the primary objective of this study is to establish a program for the molecular profiling of patients with advanced cancer, with the goals of (1) providing a comprehensive characterization of the molecular profiles of individual patients and (2) correlating molecular profile with response to phase i therapies. specimens will be received from the lab07-0817 (tissue bank) protocol in the department of investigational cancer therapeutics. note that this study is considered an umbrella protocol to systematically enroll phase i patients for molecular profiling analysis and correlate the results with treatment outcomes. the impact trial is not a treatment protocol. secondary objectives 1. to characterize advanced cancer by delineating genetic mutations, amplifications, translocations, and other defining molecular patient characteristics. 2. to assess the antitumor effects of treatments by tumor responses using the world health organization (who) or response evaluation criteria in solid tumors (recist) criteria and/or any other clinical benefits, including progression-free survival and overall survival, demonstrated in phase i clinical trials. 3. to correlate molecular profiles of patients with evidence of antitumor activity (complete remission, partial remission, prolonged stable disease, or overall survival) to define subsets of patients who will respond to specific therapies in clinical trials of novel agents. 4. to correlate molecular profiles with toxicities induced by investigational agents to define subsets of patients who may or may not be candidates for treatment with these agents in the future.

the prognosis of patients with advanced metastatic malignancies is poor, and their median survival, irrespective of diagnosis, is approximately 8.8 months (95% confidence interval, 7.4 to 10.9 months). in recent years there has been increased interest in novel agents. elucidating the molecular basis of advanced cancer will lead to the development of potentially curative strategies for these diseases aimed at the specific molecular and genetic aberrations characteristic of specific tumors. this study is a molecular profiling analyses of the patients' stored samples and will not involve more than minimal risk to the subjects. subjects are at no more than minimal risk because only leftover blood, tissue, and patient data will be used for this study, and all patient data will be kept confidential.

Eligibility criteria:
inclusion criteria: 1) any patient seen in the department of investigational cancer therapeutics is eligible. patients who have blood or tissue samples collected must be registered on the tissue bank protocol (lab07-0817). exclusion criteria: n/a

Keywords: advanced cancer initiative for molecular profiling in advanced cancer therapy impact molecular profile-based study investigational cancer therapeutics program molecular profiling phase i therapies tissue bank
study for the validation of a new biomarker to determine predisposition to infections in patients with acute myocardial infarction.

Conditions: Infections in Acute Myocardial Infarction Patients

Summary: prospective biomedical research study

the aim is to validate a new biomarker, based on the levels of dnamit present in blood, to assess the predisposition of an individual to suffer an infection. to validate this hypothesis, the dnamit levels of patients with myocardial infarction will be analysed and their relationship with the probability of these patients developing an infectious process or not.

Eligibility criteria:
inclusion criteria: * patients who have suffered ami or cardiorespiratory arrest after ami, have been admitted to hospital within the first 24 hours of the event and are required to be admitted to any critical care unit. in addition, one of the following criteria must be met: 1. symptoms of cardiac ischaemia. 2. new ischaemic patterns in the ecg. 3. development of pathological qw waves on the ecg. 4. obvious suspicion or loss of myocardial viability or new abnormal motility regions in a pattern consistent with ischaemic pathology. 5. intracoronary thrombus detected on angiography or autopsy. 2. they must be of legal age, have read the patient information sheet (hip) and have signed the informed consent (ic). depending on the group in which they are to be classified, patients must meet specific inclusion criteria: group a: patients who have suffered mi (myocardial infarction), are in the critical unit and their dnamit values are below 0.25-105 copies. group b: patients who have suffered an mi, are in the critical unit and their mtdna values are above 0.25-105 copies. exclusion criteria: patients who meet any of the following criteria shall not be eligible for inclusion in the clinical trial: 1. chronic inflammatory diseases 2. transplantation of any organ (except cornea). 3. patients receiving or who have received in the last 3 months anti-inflammatory, immunosuppressive or biological treatment targeting the immune system (tnf blockers, anakinra, rituximab, abatacept or tocilizumab), except nsaids and colchicine. 4. patients with overt and/or severe immunocompromise 5. history of chronic kidney or liver disease (dialysis or creatinine clearance \< 30%). 6. decompensated diabetes 7. active tumour process. patients considered to be in complete remission may be included in the study. 8. major surgical intervention (in the 3 months prior to inclusion in the study). 9. pregnancy, childbirth or breastfeeding in the last 3 months. 10. symptomatic patients with type iv heart failure (nyha). 11. life expectancy of less than 3 months. 12. long-term urinary catheter or vascular catheter wearers
scale validation study for prediction of relapse and short term rehospitalization in patients with schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to establish and validate a scale/model that can be used to evaluate the duration of time and factors between short term hospital treatment and subsequent relapse periods in patients with schizoaffective/schizophreniform disorders.

this is an epidemiological (study of the distribution and determinants of health-related states or events in defined population), multicenter (study conducted at multiple sites), observational (study in which patients are observed), cross-sectional (observation of all patients at one specific point in time), prospective (in which the patients are first identified and then followed forward as time passes) study. the sources of information in the study are units medical short stay psychiatric hospitalization or the acute care of the whole country, and clinical data of the patient at discharge. no intervention will be provided in this study. the general data (age range, gender, highest level of educational attainment, level of family support, substance abuse, events stressors, type of schizophrenia according to dsm-iv criteria \[diagnostic and statistical manual fourth\], etc) of approximately 2000 schizophrenia and schizoaffective disorder / schizophreniform patients will be collected in this study. no special tests will be done during the study. the study will collect patients' data in electronic data collection workbook and model validation will be used at 6 and 12 months to confirm no relapse / hospitalization. the study observation period corresponds to the 3 years preceding the current relapse and current income (current hospitalization period) and 12 months after admission.

Eligibility criteria:
inclusion criteria: * patients with schizophrenia or schizoaffective disorder of more than 2 years evolution and who find themselves admitted in a short-term psychiatric hospitalization unit or acute unit exclusion criteria: * other patients with a psychiatric pathology different to schizophrenia, schizoaffective/schizophreniform disorders * patients with schizophrenia or schizoaffective/schizophreniform disorders of 2 years, or less evolution * pregnant, lactating, or planning to become pregnant within the next 12 months

Keywords: schizophrenia mental disorder schizoaffective disorder schizophreniform disorder epidemiological study scale validation relapse short term hospitalization pre-cog rissch4075
nifedipine versus magnesium sulfate for prevention of preterm labor in symptomatic placenta previa

Conditions: Placenta Previa

Summary: antepartum hemorrhage is defined as bleeding from or within the female genital tract, occurring from 28+0 weeks of pregnancy and till delivery of the fetus. it occurs in 3-5% of pregnancies and is an important cause of perinatal and maternal morbidity and mortality worldwide

there are many tocolytic agents may have a role in conservative management of placenta previa such as magnesium sulfate, calcium channel blockers and β-sympathormimetics. in 2004 sharma suggests that ritodrine hydrochloride in patients with symptomatic placenta previa tends to prolong the pregnancy and result in an increase in birth weight of the babies without causing any adverse effect on the mother and fetus

Eligibility criteria:
inclusion criteria: * estimated gestational age : between 28 weeks and 37 week's gestation * confirmed placenta previa; either major or minor degrees. * placenta previa with preterm uterine contractions exclusion criteria: * severe attack of bleeding requiring an immediate intervention. * fetal heart rates instability or non-reassuring tracing * intrauterine fetal death or major fetal anomalies. * if associated with abruptio placentae * patients with known bleeding disorders or on anticoagulant therapy * patients with severe medical disorders as myasthenia gravis documented magnesium toxicity.
intravenous tranexamic acid versus pericervical tourniquet to decrease blood loss in trans-abdominal myomectomy

Conditions: Post Operative Hemorrhage

Summary: intravenous tranexamic acid versus pericervical tourniquet to decrease blood loss in trans-abdominal myomectomy

this study aims at comparing between different methods to decrease blood loss in trans-abdominal myomectomy. this study compares between medical (intravenous tranexamic acid administration) and non medical (pericervical tourniquet) methods in decreasing blood loss intra operative

Eligibility criteria:
inclusion criteria: * • women in the reproductive age (20 - 40 years) diagnosed as having uterine fibroids who are consenting to have trans-abdominal myomectomy in the postmenstrual period diagnosed by: clinical symptoms and signs: * abnormal uterine bleeding (menorrhagia or (and) metrorrhagia). * pain (dull aching lower abdominal pain or dysmenorrhea). * pressure symptoms (dyspareunia, dysuria, dyschezia or (and) backache). * progressive abdominal enlargement (abdominal swelling). all women with clinical presentation suggestive of uterine fibroid will undergo abdominal and trans-vaginal ultrasound to confirm the clinical diagnosis and to exclude patients with: * submucous uterine myomas. * cervical or supracervical myomas. * broad ligamentary and pedunculated myomas. * associated pelvic pathology. ultrasound criteria of uterine fibroids of included patients: * maximum diameter of the largest fibroid is greater than 4cm. * maximum number of uterine myomas is not to be more than 5 myomas. * uterine fibroid may be subserous or intramural. exclusion criteria: * obesity (body mass index \>30 kg/m2). * cardiac, endocrine, pulmonary or hematological disease (including anemia; hemoglobin level below 10gm/dl). * patients known to be allergic to tranexamic acid. * patients who received pre-operative hormonal therapy (such as a gnrh analogue). * patients presented by or with suspected malignant gynecological disease. * patients diagnosed as having submucous uterine fibroids, cervical or supracervical fibroids, broad ligamentary fibroids and pedunculated fibroids. * patients with contraindication to general anaesthesia. * patients with positive pregnancy test. * virgin patients.
study of 3d scanning for adolescent scoliosis

Conditions: Scoliosis

Summary: the investigators aim to validate three-dimensional topographical scanning technology as a tool for evaluation of scoliosis. through the incorporation of 3d topographical technology in the measurement of deformity, the investigators hope to validate a novel approach to quantify deformity progression and provide an accessible alternative to traditional radiographic workup.

the study design will be prospective observational. patients 10 to 18 years old being evaluated or followed for scoliosis will be included. those unable to complete the consent and assent processes will not be enrolled. members of the research team will review the clinic schedule through epic each week to identify eligible patients. member of the patient's care team, such as the physician, will introduce the study to the patient. if the patient and the patient's caregivers are interested in learning more and/or participating, a member of the research team will provide study-related information and obtain informed consent via written or electronic consent, assent, and, if necessary, short form consent. if a patient consents to participate, members of the research team will conduct the 3d topographical scan in a private room in the clinic. this involves 360 degree scans using a smartphone camera. participants will also receive any standard of care x-rays during the visit. the investigators will then analyze the ability of the 3d smartphone scan to estimate the cobb angle measured on the x-ray, to infer the magnitude of the scoliosis deformity.

Eligibility criteria:
inclusion criteria: * ages 10 and 18 years old exclusion criteria: * scoliosis caused by another condition (e.g., secondary scoliosis) * parents/guardians unable to consent * english is not the primary language (to avoid miscommunication)

Keywords: scoliosis topographical scanning
erythema toxicum neonatorum in newborns and the development of asthma

Conditions: Asthma; Erythema Toxicum Neonatorum

Summary: erythema toxicum neonatorum (etn) is a common skin finding that affects healthy full-term babies. several authors have commented on the possible relationship between etn and the development of atopic conditions, such as atopic dermatitis or respiratory disease later in life. there is a paucity of research addressing this issue.


Eligibility criteria:
inclusion criteria: * children between the ages of 3-9 years who have had at least 2 asthma diagnoses within the last 2 years. * control subjects will be age matched and without an asthma diagnosis. exclusion criteria: * children without accessible medical records
topical jelly and intracameral anesthesia versus subtenon anesthesia, in cataract surgery

Conditions: Cataract Surgery Anesthesia

Summary: the options for anesthesia in cataract surgery described are: general, regional or local. the local strategy, it may be by periocular blocking(subtenon, peribulbar or retrobulbar), subconjunctival or topical. the risks faced by subconjunctival, peribulbar or retrobulbar, have made subtenon and topical strategies the most used. likewise, to improve the effectiveness of the topical strategy was added gel topical lidocaine and intracameral dose of lidocaine. subtenon and topical anesthesia are two safe strategies and there were performed multiple studies showing that both are effective in controlling pain, but showing a slight superiority of subtenon. this difference does not appear to be clinically significant. in turn, the addition of gel and intracameral anesthesia, improved pain control. however, lack evidence to compare patient preference when using topical gel and intracameral anesthesia versus sub-tenon anesthesia. multiple advantages has the topical anesthesia. besides being a safe strategy for the patient, offers a rapid visual recovery, no generates blepharoptosis or diplopia postoperatively, subconjunctival hemorrhage and chemosis. because of this the investigators plan to conduct a study comparing the efficacy of gel topical and intracameral anesthesia versus subtenon anesthesia in cataract surgery with scleral incision, assessing the patient's preference hypothesis: topical administration of lidocaine in gel and intracameral anesthesia is a better strategy that subtenon anesthesia in cataract surgery


Eligibility criteria:
inclusion criteria: * bilateral cataract exclusion criteria: * refuse to participate, high surgical risk (asa 4 or 5), allergy to lidocaine or other amide local anesthesics, inability to understand the informed consent, coagulation abnormalities, prior ophthalmologic surgery, small pupil, fuchs dystrophy, lens luxation, uveitis